|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CDC42EP2 |
Gene summary for CDC42EP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CDC42EP2 | Gene ID | 10435 |
| Gene name | CDC42 effector protein 2 | |
| Gene Alias | BORG1 | |
| Cytomap | 11q13.1 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | O14613 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10435 | CDC42EP2 | LZE4T | Human | Esophagus | ESCC | 2.29e-05 | 3.14e-01 | 0.0811 |
| 10435 | CDC42EP2 | LZE20T | Human | Esophagus | ESCC | 1.68e-26 | 9.72e-01 | 0.0662 |
| 10435 | CDC42EP2 | LZE21T | Human | Esophagus | ESCC | 5.86e-04 | 2.32e-01 | 0.0655 |
| 10435 | CDC42EP2 | P2T-E | Human | Esophagus | ESCC | 6.20e-03 | 9.95e-02 | 0.1177 |
| 10435 | CDC42EP2 | P4T-E | Human | Esophagus | ESCC | 3.38e-16 | 4.91e-01 | 0.1323 |
| 10435 | CDC42EP2 | P5T-E | Human | Esophagus | ESCC | 3.10e-13 | 4.08e-01 | 0.1327 |
| 10435 | CDC42EP2 | P8T-E | Human | Esophagus | ESCC | 6.58e-07 | 1.59e-01 | 0.0889 |
| 10435 | CDC42EP2 | P9T-E | Human | Esophagus | ESCC | 1.49e-04 | 2.06e-01 | 0.1131 |
| 10435 | CDC42EP2 | P10T-E | Human | Esophagus | ESCC | 1.88e-03 | 7.09e-02 | 0.116 |
| 10435 | CDC42EP2 | P12T-E | Human | Esophagus | ESCC | 1.78e-33 | 7.01e-01 | 0.1122 |
| 10435 | CDC42EP2 | P15T-E | Human | Esophagus | ESCC | 6.21e-22 | 5.00e-01 | 0.1149 |
| 10435 | CDC42EP2 | P16T-E | Human | Esophagus | ESCC | 1.62e-07 | 2.27e-01 | 0.1153 |
| 10435 | CDC42EP2 | P19T-E | Human | Esophagus | ESCC | 1.71e-03 | 4.41e-01 | 0.1662 |
| 10435 | CDC42EP2 | P20T-E | Human | Esophagus | ESCC | 6.35e-05 | 5.98e-02 | 0.1124 |
| 10435 | CDC42EP2 | P21T-E | Human | Esophagus | ESCC | 8.11e-09 | 2.80e-01 | 0.1617 |
| 10435 | CDC42EP2 | P22T-E | Human | Esophagus | ESCC | 3.28e-07 | 1.10e-01 | 0.1236 |
| 10435 | CDC42EP2 | P23T-E | Human | Esophagus | ESCC | 6.13e-09 | 3.47e-01 | 0.108 |
| 10435 | CDC42EP2 | P24T-E | Human | Esophagus | ESCC | 9.87e-03 | 1.31e-01 | 0.1287 |
| 10435 | CDC42EP2 | P26T-E | Human | Esophagus | ESCC | 1.77e-07 | 2.27e-01 | 0.1276 |
| 10435 | CDC42EP2 | P27T-E | Human | Esophagus | ESCC | 7.49e-03 | 1.49e-01 | 0.1055 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0043254111 | Esophagus | ESCC | regulation of protein-containing complex assembly | 278/8552 | 428/18723 | 3.81e-16 | 2.77e-14 | 278 |
| GO:0031334111 | Esophagus | ESCC | positive regulation of protein-containing complex assembly | 166/8552 | 237/18723 | 2.06e-14 | 1.07e-12 | 166 |
| GO:1902905111 | Esophagus | ESCC | positive regulation of supramolecular fiber organization | 142/8552 | 209/18723 | 5.51e-11 | 1.76e-09 | 142 |
| GO:1902903111 | Esophagus | ESCC | regulation of supramolecular fiber organization | 237/8552 | 383/18723 | 9.06e-11 | 2.75e-09 | 237 |
| GO:005149520 | Esophagus | ESCC | positive regulation of cytoskeleton organization | 147/8552 | 226/18723 | 2.93e-09 | 6.38e-08 | 147 |
| GO:0051258111 | Esophagus | ESCC | protein polymerization | 183/8552 | 297/18723 | 1.94e-08 | 3.75e-07 | 183 |
| GO:000701527 | Esophagus | ESCC | actin filament organization | 259/8552 | 442/18723 | 2.37e-08 | 4.50e-07 | 259 |
| GO:0032273111 | Esophagus | ESCC | positive regulation of protein polymerization | 95/8552 | 138/18723 | 2.97e-08 | 5.57e-07 | 95 |
| GO:003253520 | Esophagus | ESCC | regulation of cellular component size | 227/8552 | 383/18723 | 4.77e-08 | 8.60e-07 | 227 |
| GO:000726510 | Esophagus | ESCC | Ras protein signal transduction | 201/8552 | 337/18723 | 1.44e-07 | 2.30e-06 | 201 |
| GO:0032970111 | Esophagus | ESCC | regulation of actin filament-based process | 231/8552 | 397/18723 | 2.91e-07 | 4.20e-06 | 231 |
| GO:0032956111 | Esophagus | ESCC | regulation of actin cytoskeleton organization | 210/8552 | 358/18723 | 4.40e-07 | 6.00e-06 | 210 |
| GO:0032271111 | Esophagus | ESCC | regulation of protein polymerization | 143/8552 | 233/18723 | 9.21e-07 | 1.17e-05 | 143 |
| GO:011005327 | Esophagus | ESCC | regulation of actin filament organization | 166/8552 | 278/18723 | 1.54e-06 | 1.85e-05 | 166 |
| GO:002260420 | Esophagus | ESCC | regulation of cell morphogenesis | 180/8552 | 309/18723 | 5.19e-06 | 5.45e-05 | 180 |
| GO:003134616 | Esophagus | ESCC | positive regulation of cell projection organization | 201/8552 | 353/18723 | 1.19e-05 | 1.11e-04 | 201 |
| GO:003083819 | Esophagus | ESCC | positive regulation of actin filament polymerization | 66/8552 | 99/18723 | 1.96e-05 | 1.72e-04 | 66 |
| GO:000815420 | Esophagus | ESCC | actin polymerization or depolymerization | 130/8552 | 218/18723 | 2.19e-05 | 1.88e-04 | 130 |
| GO:0030041110 | Esophagus | ESCC | actin filament polymerization | 114/8552 | 191/18723 | 6.46e-05 | 4.92e-04 | 114 |
| GO:000806419 | Esophagus | ESCC | regulation of actin polymerization or depolymerization | 112/8552 | 188/18723 | 8.31e-05 | 6.06e-04 | 112 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CDC42EP2 | SNV | Missense_Mutation | c.158G>C | p.Gly53Ala | p.G53A | O14613 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CDC42EP2 | SNV | Missense_Mutation | c.98N>T | p.Pro33Leu | p.P33L | O14613 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| CDC42EP2 | SNV | Missense_Mutation | c.541N>A | p.Leu181Met | p.L181M | O14613 | protein_coding | tolerated(0.06) | possibly_damaging(0.65) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| CDC42EP2 | SNV | Missense_Mutation | c.111N>A | p.Phe37Leu | p.F37L | O14613 | protein_coding | deleterious(0.05) | probably_damaging(0.939) | TCGA-44-5645-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CDC42EP2 | SNV | Missense_Mutation | novel | c.307N>G | p.Leu103Val | p.L103V | O14613 | protein_coding | tolerated(0.49) | benign(0.152) | TCGA-55-8089-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| CDC42EP2 | SNV | Missense_Mutation | novel | c.614N>A | p.Ser205Asn | p.S205N | O14613 | protein_coding | tolerated_low_confidence(0.21) | benign(0.003) | TCGA-77-A5GB-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| CDC42EP2 | SNV | Missense_Mutation | novel | c.202A>G | p.Thr68Ala | p.T68A | O14613 | protein_coding | tolerated(0.49) | possibly_damaging(0.642) | TCGA-CR-7402-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | SD |
| CDC42EP2 | SNV | Missense_Mutation | c.305C>A | p.Pro102His | p.P102H | O14613 | protein_coding | deleterious(0) | probably_damaging(0.956) | TCGA-HU-8602-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Chemotherapy | xeloda | CR | |
| CDC42EP2 | deletion | Frame_Shift_Del | novel | c.218delC | p.Pro73LeufsTer91 | p.P73Lfs*91 | O14613 | protein_coding | TCGA-HU-A4GX-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | taxol | SD | ||
| CDC42EP2 | SNV | Missense_Mutation | novel | c.424C>A | p.Pro142Thr | p.P142T | O14613 | protein_coding | tolerated(0.28) | benign(0.154) | TCGA-EM-A2CJ-01 | Thyroid | thyroid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |